Drug intelligence / Profile preview

CLS239

Development stage: Preclinical
Lead developer: Cellusion
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

CLS239 is a research-stage cell therapy candidate being developed by Cellusion for the treatment of oncology. The drug is based on Cellusion's proprietary **FRiEND Tech** (Function added Regenerative iPSC-derived ENdothelial cell Technology) platform, which involves the creation of function-added endothelial cell substitutes derived from induced pluripotent stem cells (iPSCs). While Cellusion's primary focus is on corneal regenerative medicine (using their CECSi platform), CLS239 represents an expansion of this technology into the oncology space, utilizing engineered endothelial cells to potentially deliver therapeutic payloads or modulate the tumor microenvironment.

Beyond the preview

Go deeper on CLS239.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLS239.

Explore the full profile